Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839393 | 0.94 | PTGS2 (0.46) | PTGS2MAPTALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL14821474 | 0.93 | MAPT (0.47) | PTGS2MAPTALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL12810501 | 0.89 | PTGS2 (0.41) | PTGS2MAPTALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL14364375 | 0.87 | PTGS2 (0.50) | PTGS2MAPTALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL16270524 | 0.85 | GAA (0.51) | MAPTALDH1A1KMT2AL3MBTL1MEN1 | |
| SCHEMBL832556 | 0.84 | CYP3A4 (0.46) | CYP2C19POLBGAAPPARDSMN1; SMN2 | |
| SCHEMBL2116437 | 0.82 | PTGS2 (0.66) | PTGS2MAPTALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL13246956 | 0.82 | ALDH1A1 (0.51) | ALDH1A1CYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL7406335 | 0.81 | ALOX15 (0.55) | MAPTALDH1A1KMT2AMEN1PPARD | |
| SCHEMBL8484161 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP2C9CYP2C19L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45548-E1 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-RE45548-E1 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-8846845-B2 | Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices | BEZWADA BIOMEDICAL, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846845-B2 | Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices | BEZWADA BIOMEDICAL, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2298235-B1 | Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices | BEZWADA BIOMEDICAL LLC (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-2298235-B1 | Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices | BEZWADA BIOMEDICAL LLC (US) | 2013-11-06 | — | — | EP | disclosed |
| US-8409559-B2 | Functionalized drugs and polymers derived therefrom | Bezwada Biomedical, Inc. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8409559-B2 | Functionalized drugs and polymers derived therefrom | Bezwada Biomedical, Inc. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8409559-B2 | Functionalized drugs and polymers derived therefrom | Bezwada Biomedical, Inc. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120158127-A1 | BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES | BEZWADA BIOMEDICAL, LLC (US) | 2012-06-21 | — | — | US | disclosed |
| EP-0691959-B1 | HETEROCYCLIC DERIVATIVES AS PLATELET AGGREGATION INHIBITORS | ZENECA LTD (GB) | 1998-07-22 | — | — | EP | disclosed |
| US-5753659-A | ANTICOAGULANTS FOR BLOOD DISORDER, CARDIOVASCULAR DISORDER, THROMBOSIS, | ZENECA LIMITED (GB) | 1998-05-19 | — | — | US | disclosed |
| US-5750754-A | TERTIARY BUTYL 3-METHYL-4-SUBSTITUTED BUTYRATE; CHEMICAL INTERMEDIATES FOR ANTICAOGULANT DRUGS | ZENECA LIMITED (GB) | 1998-05-12 | — | — | US | disclosed |
| US-5728701-A | INHIBIT PLATELET AGGREGATION | ZENECA LIMITED (GB) | 1998-03-17 | — | — | US | disclosed |
| EP-0825184-A1 | Heterocyclic derivatives as platelet aggregation inhibitors | ZENECA LIMITED (GB) | 1998-02-25 | — | — | EP | disclosed |
| US-5652242-A | 3-METHYL-4-(4-(4-(4-PYRIDYL)PIPERAZIN-1-YL)PHENOXY)BURYIC ACID, AMIDE OR ESTER; INHIBITORS OF BINDING OF FIBRINOGEN TO GLYCOPROTEIN | ZENECA LIMITED (GB) | 1997-07-29 | — | — | US | disclosed |
| US-5563141-A | INHIBIT CELL ADHESION FOR EXAMPLE, PLATELET AGGRE GATION | ZENECA LIMITED (GB) | 1996-10-08 | — | — | US | disclosed |
| US-5556977-A | ANTIAGGLOMERANTS FOR CELLS, ANTICOAGULANTS, ANTIISCHEMIC AGENTS USING PYRIDINYLPIPERAZINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-09-17 | — | — | US | disclosed |
| EP-0691959-A1 | HETEROCYCLIC DERIVATIVES AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-17 | — | — | EP | disclosed |
| WO-1994022834-A1 | HETEROCYCLIC DERIVATIVES AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120158127-A1 | BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES | HAO2, AOC2, AOC1 | PTGS2 320/4885MAPT 2702/4885ALDH1A1 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.